CERC 501

Drug Profile

CERC 501

Alternative Names: CERC501; LY 2456302

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Janssen Pharmaceuticals; Rockefeller University
  • Class Drug withdrawal therapies
  • Mechanism of Action Opioid kappa receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder; Smoking withdrawal
  • Phase I Alcoholism
  • Clinical Phase Unknown Cocaine abuse

Most Recent Events

  • 01 Jan 2018 Cerecor and Yale University completes a phase II trial for Smoking withdrawal in USA (PO) (NCT02800928)
  • 17 Aug 2017 Janssen Pharmaceuticals acquires CERC 501 from Cerecor
  • 30 May 2017 Clinical trials in Cocaine abuse in USA (PO) prior to May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top